|
[1]BJORNSSON ES, BERGMANN OM, BJORNSSON HK, et al.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.
|
|
[2]KUZU UB, OZTAS E, TURHAN N, et al.Clinical and histological features of idiosyncratic liver injury:Dilemma in diagnosis of autoimmune hepatitis[J].Hepatol Res, 2016, 46 (4) :277-291.
|
|
[3]LICATA A, MAIDA M, CABIBI D, et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis:a retrospective cohort study[J].Dig Liver Dis, 2014, 46 (12) :1116-1120.
|
|
[4]BJORNSSON E, TALWALKAR JA, TREEPRASERTSUK S, et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis[J].Hepatology, 2010, 51 (6) :2040-2048.
|
|
[5]PARHAM LR, BRILEY LP, LI L, et al.Comprehensive genomewide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07∶01[J].Pharmacogenomics J, 2016, 16 (2) :180-185.
|
|
[6]van GERVEN NM, de BOER YS, ZWIERS A, et al.HLA-DRB1*03∶01 and HLA-DRB1*04∶01 modify the presentation and outcome in autoimmune hepatitis type-1[J].Genes Immun, 2015, 16 (4) :247-252.
|
|
[7]STEPHENS C, CASTIELLA A, GOMEZ-MORENO EM, et al.Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis:the influence of human leucocyte antigen alleles[J].Pharmacogenet Genomics, 2016, 26 (9) :414.
|
|
[8]de BOER YS, KOSINSKI AS, URBAN TJ, et al.Features of autoimmune hepatitis in patients with drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2016, 15 (1) :103.
|
|
[9]HISAMOCHI A, KAGE M, IDE T, et al.An analysis of drug induced liver injury, which showed histological findings similar to autoimmune hepatitis[J].J Gastroenterol, 2016, 51 (6) :597-607.
|
|
[10]SAKAGUCHI S, SAKAGUCHI N, ASANE M, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) .Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol, 1995, 155 (3) :1151.
|
|
[11]TAN Z, QIAN X, JIANG R, et al.IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation[J].J Immunol, 2013, 191 (4) :1835-1844.
|
|
[12]CHANG SH, REYNOLDS JM, PAPPU BP, et al.Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E[J].Immunity, 2011, 35 (4) :611-621.
|
|
[13]HUANG J, YUAN Q, ZHU H, et al.IL-17C/IL-17RE augments T cell function in autoimmune hepatitis[J].J Immunol, 2016, 198 (2) :669-680.
|
|
[14]LONGHI MS, MA Y, GRANT CR, et al.T-regs in autoimmune hepatitis-systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile[J].J Autoimmun, 2013, 41:146-151.
|
|
[15]HENINGER AK, THEIL A, WILHELM C, et al.IL-7 abrogates suppressive activity of human CD4+CD25+Fox P3+regulatory Tcells and allows expansion of alloreactive T cells[J].J Immunol, 2012, 189 (12) :5649-5658.
|
|
[16]MORIKAWA H, SAKAGUCHI S.Genetic and epigenetic basis of Treg cell development and function:from a Fox P3-centered view to an epigenome-defined view of natural Treg cells[J].Immunol Rev, 2014, 259 (1) :192-205.
|
|
[17]SHEVACH EM, THORNTON AM.t Tregs, p Tregs, and i Tregs:similarities and differences[J].Immunol Rev, 2014, 259 (1) :88-102.
|
|
[18]PARK MK, PARK JS, PARK EM, et al.Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis[J].Arthritis Rheumatol, 2014, 66 (5) :1195-1207.
|
|
[19]FENG H, YIN J, HAN YP, et al.Sustained changes of Treg and Th17cells during interferon-αtherapy in patients with chronic hepatitis B[J].Viral Immunol, 2015, 28 (8) :412-417.
|
|
[20]HOOFNAGLE JH, SHERKER AH.Hepatitis C:down but not out[J].Ann Intern Med, 2017, 166 (9) :675.
|
|
[21]VUPPALANCHI R, GOULD RJ, WILSON LA, et al.Clinical significance of serum autoantibodies in patients with NAFLD:results from the nonalcoholic steatohepatitis clinical research network[J].Hepatol Int, 2012, 6 (1) :379-385.
|
|
[22]SUZUKI A, BRUNT EM, KLEINER DE, et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology, 2011, 54 (3) :931-939.
|
|
[23]TAKEDA K, ODA M, OKADA T, et al.Over-the-counter drug induced autoimmune hepatitis[J].Intern Med, 2016, 55 (10) :1293-1297.
|
|
[24]LANG ZW.Pathological advances in autoimmune liver disease[J].JClin Hepatol, 2012, 28 (5) :326-331. (in Chinese) 郎振为.自身免疫性肝病的病理学新进展[J].临床肝胆病杂志, 2012, 28 (5) :326-331.
|
|
[25]STINE JG, LEWIS JH.Current and future directions in the treatment and prevention of drug-induced liver injury:a systematic review[J].Expert Rev Gastroenterol Hepatol, 2015, 10 (4) :1.
|
|
[26]STINE JG, INTAGLIATA N, SHAH NL, et al.Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis[J].Dig Dis Sci, 2015, 60 (4) :1031-1035.
|
|
[27]LICATA A, MAIDA M, CABIBI D, et al.Clinical features and outcomes of patients with drug-induced autoimmune hepatitis:a retrospective cohort study[J].Dig Liver Dis, 2014, 46 (12) :1116-1120.
|
|
[28]AIZAWA Y, HOKARI A.Autoimmune hepatitis:current challenges and future prospects[J].Clin Exp Gastroenterol, 2017, 10:9-18.
|
|
[29]LIU ZX, KAPLOWITZ N.Immune-mediated drug-induced liver disease[J].Clin Liver Dis, 2002, 6 (3) :755-774.
|
|
[30]WEILERNORMANN C, SCHRAMM C.Drug induced liver injury and its relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :747-749.
|
|
[31]CZAJA AJ.Drug-induced autoimmune-like hepatitis[J].Dig Dis Sci, 2011, 56 (4) :958-976.
|
|
[32]LUCENA MI, MOLOKHIA M, SHEN Y, et al.Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles[J].Gastroenterology, 2011, 141 (1) :338-347.
|
|
[33]BESSONE F, HERNANDEZ N, SANCHEZ A.The Spanish-latin American DILI network:preliminary results from a collaborative strategic initiative[J].J Hepatol, 2012, 58 (Suppl 1) :s212-s213.
|
|
[34]ANDRADE RJ, MEDINA-CALIZ I, STEPHENS C.La hepatotoxicidad recurrente seasocia frecuentemente a manifestaciones de autoinmunidad[J].Gastroenterol Hepatol, 2013, 36:84.
|
|
[35]OHMOTO K, YAMAMOTO S.Drug-induced liver injury associated with antinuclear antibodies[J].Scand J Gastroenterol, 2002, 37 (11) :1345-1346.
|
|
[36]CRISMALE JF, STUECK A, BANSAL M.Toxin-induced autoimmune hepatitis caused by raw cashew nuts[J].ACG Case Rep J, 2016, 3 (4) :133.
|
|
[37]YANG MR, LIU B, ZHANG GS, et al.Bicyclol combined with magnesium isoglycyrrhizinate for drug-induced autoimmune hepatitis[J].J Chin Practical Diagn and Ther, 2017, 31 (3) :278-290. (in Chinese) 杨美荣, 刘斌, 张国顺, 等.双环醇联合异甘草酸镁治疗药物诱导自身免疫性肝炎效果观察[J].中华实用诊断与治疗杂志, 2017, 31 (3) :278-290.
|
|
[38]ZHANG GS, SHANG H, GAO BX, et al.Clinical study of isoglycyrrhizinate with thymosinα1 in treatment of drug-induced autoimmune hepatitis[J].Chin J Gastroenterol Hepatol, 2012, 21 (7) :649-651. (in Chinese) 张国顺, 尚华, 高宝霞, 等.异甘草酸镁联合胸腺肽α1治疗药物诱导自身免疫性肝炎的临床研究[J].胃肠病学和肝病学杂志, 2012, 21 (7) :649-651.
|
|
[39]YAN ZH, WANG YM, TANG B, et al.Meta-analysis of magnesium isoglycyrrhizinate combined with nucleoside ana-logues in patients with chronic hepatitis B[J].Chin J Hepatol, 2014, 22 (2) :108-112. (in Chinese) 晏泽辉, 王宇明, 汤勃, 等.异甘草酸镁联合核苷类似物治疗慢性乙型肝炎的荟萃分析[J].中华肝脏病杂志, 2014, 22 (2) :108-112.
|
|
[40]KLEINER DE, BERMAN D.Pathologic changes in ipilimumabrelated hepatitis in patients with metastatic melanoma[J].Dig Dis Sci, 2012, 57 (8) :2233.
|
|
[41]CHMIEL KD, SUAN D, LIDDLE C, et al.Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy[J].J Clin Oncol, 2011, 29 (9) :237-240.
|
|
[42]YANG F, WANG Q, JIA J, et al.Autoimmune hepatitis:east meets west.[J].J Gastroenterol Hepatol, 2015, 30 (8) :1230.
|
|
[43]ZHANG H, LIU Y, BIAN Z, et al.The critical role of myeloidderived suppressor cells and FXR activation in immune-mediated liver injury[J].Autoimmun, 2014, 53:55-66.
|
DownLoad: